Learn about idiopathic pulmonary fibrosis, its symptoms, diagnosis, and treatment options for managing this lung disease.

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...

Fibrosis predicts post-surgical risk in aortic stenosis, reinforcing its role in guiding treatment decisions for both sexes.

Solute carrier (SLC) family transporters are crucial transmembrane proteins responsible for transporting various molecules, ...

The American College of Chest Physicians (CHEST), the PF Warriors, the Rare Disease Diversity Coalition (RDDC)-a program at the Black Woman's Health Imperative-and the National Association of ...

Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...

Once-daily vanzacaftor-tezacaftor-deutivacaftor was safe and well-tolerated in children with cystic fibrosis, while ...

A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Feb. 6, 2025 — Despite new medication, cystic fibrosis often leads to permanent lung damage. Researchers have discovered that the disease causes changes in the immune system early in life ...

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...